Medical Patent News RSS Feed - Medical Patent News

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

Can-Fite BioPharma receives Notice of Allowance for patent covering manufacturing method of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced the U.S. Patent & Trademark Office has issued a Notice of Allowance to the Company for an important manufacturing method patent for its drug candidate CF101. [More]
Kit Check announces issuance of four meaningful patents by U.S. Patent and Trademark Office

Kit Check announces issuance of four meaningful patents by U.S. Patent and Trademark Office

Kit Check, the leader in hospital pharmacy kit processing and medication tracking software, today announced that the United States Patent and Trademark Office has issued the company two meaningful patents, with two additional patents set to issue on June 16, 2015. These awards represent a robust portfolio of intellectual property (IP) related to the Kit Check product. [More]
Investigators patent novel technique for detecting carcinomas in oral mucosa

Investigators patent novel technique for detecting carcinomas in oral mucosa

Malignant tumours of the oral cavity are the sixth leading cause of cancer-related deaths worldwide. As such, a fast and accurate diagnosis is key to maximising the probability of successful treatment and the hope and quality of life of patients. [More]
RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

RXi Pharmaceuticals receives Notice of Allowance from USPTO for novel, self-delivering RNAi platform

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, today announced that it received a Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd‑rxRNA). [More]

Zecotek’s switchable 3D/2D optical imaging system granted U.S. Patent

Zecotek Photonics Inc., a developer of leading-edge photonics technologies for industrial, healthcare and scientific markets, is pleased to announce that the U.S. Patent office has granted U.S. Patent No. 9,055,288 to Zecotek for technology related to the Company's switchable 3D/2D optical imaging system. [More]
Ceres receives U.S. patent for genetic sequence obtained from soybean

Ceres receives U.S. patent for genetic sequence obtained from soybean

Ceres, Inc., an agricultural biotechnology company, has been awarded a U.S. patent for a genetic sequence derived from soybean, covering uses of the gene in areas such as research, product development and plant transformation. [More]
Researchers submit patent application for drug that could destroy acute lymphoblastic leukemia

Researchers submit patent application for drug that could destroy acute lymphoblastic leukemia

A patent application for a drug that could destroy the deadly childhood disease known as acute lymphoblastic leukemia — and potentially other cancers as well — has been submitted by researchers at Sandia National Laboratories, the University of Maryland and the MD Anderson Cancer Center in Houston. [More]

Spherix receives another standard-essential patent from USPTO

Spherix Incorporated -- an intellectual property development company committed to the fostering and monetization of intellectual property, today announced that the United States Patent & Trademark Office is issuing the Company another standard-essential patent. [More]
NEB announces issuance of US patent for RNA-seq technology

NEB announces issuance of US patent for RNA-seq technology

New England Biolabs, Inc. announces the issuance of United States Patent Number 8,999,677, which describes a novel method for retaining valuable strand-specific information contained within RNA transcripts. [More]
Imprimis has exclusive US commercial rights for patented Hep-Lido-A formulation

Imprimis has exclusive US commercial rights for patented Hep-Lido-A formulation

Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced it now has the exclusive US commercial rights to the patented compounded alkalinized lidocaine and heparin formulation ("Hep-Lido-A" or "HLA") for the treatment of interstitial cystitis ("IC"), commonly referred to as painful bladder syndrome ("PBS"). [More]
Stempeutics Research granted process patent in China for novel stem-cell based drug Stempeucel

Stempeutics Research granted process patent in China for novel stem-cell based drug Stempeucel

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the State Intellectual Property Office of China granted a process patent for its novel stem-cell based drug Stempeucel. [More]
Molecular Health granted European patent for novel Erythropoietin receptor

Molecular Health granted European patent for novel Erythropoietin receptor

Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth. [More]
Check-Cap announces Notice of Allowance from USPTO for endoscopy capsule technology

Check-Cap announces Notice of Allowance from USPTO for endoscopy capsule technology

Check-Cap Ltd., a clinical stage medical diagnostics company engaged in the development of a preparation-free ingestible imaging capsule that utilizes low-dose X-rays for the screening for colorectal cancer, today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office for patent application U.S. 13/825,018 entitled, "Estimation of Distances and Size of Lesions in the Colon with an Imaging Capsule." [More]
TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

TWi Pharmaceuticals, Inc. today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc. (individually and collectively, "Takeda") to settle and dismiss all outstanding patent litigation related to TWi's generic dexlansoprazole delayed release capsules for oral administration in 30 mg and 60 mg dosage strengths. [More]

Lucideon Receives ISO 17025 Accreditation for Wear Testing

Lucideon, the international materials technology company, has been awarded ISO/IEC 17025:2005 accreditation for the total wear testing of hip joints... [More]
Medtronic plans to develop stent graft system for treatment of thoracoabdominal aortic aneurysms

Medtronic plans to develop stent graft system for treatment of thoracoabdominal aortic aneurysms

The global leader in medical technology for endovascular aortic repair (EVAR), Medtronic plc today announced that it plans to develop a stent graft system for less invasive treatment of thoracoabdominal aortic aneurysms under an exclusive patent license agreement with South Dakota-based Sanford Health. [More]
JPK reports on the use of the NanoWizard® 3 AFM system at the Hebrew University of Jerusalem

JPK reports on the use of the NanoWizard® 3 AFM system at the Hebrew University of Jerusalem

JPK Instruments, a world-leading manufacturer of nanoanalytic instrumentation for research in life sciences and soft matter, reports on the use of their NanoWizard® AFM system in the Institute of Chemistry of the Hebrew University of Jerusalem... [More]
USPTO issues Cardio3 BioSciences Notice of Allowance for patent covering CAR-expressing TCR-deficient T-Cells

USPTO issues Cardio3 BioSciences Notice of Allowance for patent covering CAR-expressing TCR-deficient T-Cells

Cardio3 BioSciences, a leader in engineered cell therapies with clinical programs initially targeting indications in cardiovascular disease and oncology, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a significant patent application covering T-Cell receptor-deficient T-Cells which are engineered to express a chimeric antigen receptor. [More]
BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring files two patent applications to expand therapeutic scope of Plinabulin

BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed two new method of treatment patent applications with the United States Patent and Trademark Office to cover methods of treating brain tumors as well as cancers expressing a mutant form of RAS protein through administration of the Company’s lead compound, Plinabulin. [More]
MEDITE announces granting of German priority patent for Histology 'Lab-in-one Automation' System

MEDITE announces granting of German priority patent for Histology 'Lab-in-one Automation' System

MEDITE Cancer Diagnostics, Inc., specializing in the development, manufacturing and marketing of superior molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and related diseases announced the recent decision of the German Patent Register to grant MEDITE the German priority patent for its Histology "Lab-in-one Automation" System. [More]
Advertisement
Advertisement